🌟 We are attending #BioKorea this year! We're eager to explore new opportunities and, together with Biocom California, deepen our connections in the APAC region and the broader biotech industry. If you would like to meet with our CEO, Chorom Pak, to learn more about our platform and partnering opportunities, please don’t hesitate to reach out. Let's connect and explore potential collaborations! 🚀 #BioKorea #Biotechnology #Networking #APAC #Collaboration
Lynx Biosciences, Inc.
Biotechnology Research
San Diego, California 1,956 followers
Resolving cancer biology through integrated multi-omics.
About us
Currently incubating at Johnson & Johnson JLABS San Diego. Follow us @LynxBio.
- Website
-
http://www.lynx.bio
External link for Lynx Biosciences, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Diego, California
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Personalized Medicine, Hematological Malignancies, Multiple Myeloma, Leukemia, Companion Diagnostics, Biomarker Discovery, and Drug Discovery
Locations
-
Primary
3210 Merryfield Row
San Diego, California 92121, US
Employees at Lynx Biosciences, Inc.
Updates
-
Congratulations, Prof. Dave Beebe!
Three UW–Madison researchers — David Beebe, Guang-Hong Chen and Yoshihiro Kawaoka — have been named 2023 National Academy of Inventors fellows for their commitment to moving innovative discoveries from the lab to the marketplace.
-
Lynx Biosciences, Inc. reposted this
-
🗓️ T minus 2 days until the 65th Annual American Society of Hematology meeting & expo kicks off! Our team is eagerly anticipating four science-filled days with our peers, and we're excited to share our latest data from collaborations with Johnson & Johnson Innovative Medicine and Kite Pharma: 📢 Sat, Dec 9th, 2:45 PM: “Advancing CAR-T Therapy in Acute Lymphoblastic Leukemia: Multi-Omic Analyses of CD19-Directed CAR-T Cells Enabled By an Ex Vivo Co-Culture Platform” - https://lnkd.in/gmSQAP7W 📢 Sun, Dec 10th, 6-8 PM, our very own Dennis Wu will present: “Unraveling the Dynamics of T Cell-Dependent Bispecific Antibodies in Multiple Myeloma: Multi-Omic Insights from Primary Patient Cells” – https://lnkd.in/gnWu46hp If you're attending, let's meet up! Drop us a message or leave a comment below – we’d love to hear from you.
-
Mark your calendars! Our team is looking forward to engaging with the community at the American Society of Hematology’s 65th Annual Meeting, being held December 9-12, 2023, in San Diego, CA. 📢 We are excited to unveil our presentations at #ASH23, spotlighting the advancements we have achieved in collaboration with Johnson & Johnson Innovative Medicine and Kite Pharma; these joint presentations highlight the progress and validation of our patient-based ex vivo platform in the immune cell redirection domain. 🔗 Eager for a sneak peek? Find out more at: - “Unraveling the Dynamics of T Cell-Dependent Bispecific Antibodies in Multiple Myeloma: Multi-Omic Insights from Primary Patient Cells” – https://lnkd.in/gnWu46hp - “Advancing CAR-T Therapy in Acute Lymphoblastic Leukemia: Multi-Omic Analyses of CD19-Directed CAR-T Cells Enabled By an Ex Vivo Co-Culture Platform” - https://lnkd.in/gmSQAP7W Special thanks to our collaborators at Kite Pharma and Johnson & Johnson Innovative Medicine, and to the incredible team at JLABS @San Diego for their support, partnerships, and JPAL mentoring program. Additionally, a heartfelt acknowledgment to our dedicated team at #LynxBio, the backbone behind these transformative projects. Together, we have made significant strides and look forward to achieving more! 🙌 #ASH2023 #BloodCancer #oncology #hematology #immunooncology #immunotherapy #multiplemyeloma #MM #ALL #CARTtherapy, #immunecellredirection, #techbio #biotechnology